Medication Guide App

Generic Dulera Availability

Dulera is a brand name of formoterol/mometasone, approved by the FDA in the following formulation(s):

DULERA (formoterol fumarate; mometasone furoate - aerosol, metered;inhalation)

  • Manufacturer: MERCK SHARP DOHME
    Approval date: June 22, 2010
    Strength(s): 0.005MG/INH;0.1MG/INH [RLD], 0.005MG/INH;0.2MG/INH [RLD]

Has a generic version of Dulera been approved?

No. There is currently no therapeutically equivalent version of Dulera available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Dulera. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Use of mometasone furoate for treating lower airway passage and lung diseases
    Patent 5,889,015
    Issued: March 30, 1999
    Inventor(s): Sequeira; Joel A. & Cuss; Francis M. & Nolop; Keith B. & Chaudry; Imtiaz A. & Nagabhushan; Nagamani & Patrick; James E. & Cayen; Mitchell
    Assignee(s): Schering Corporation
    The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.
    Patent expiration dates:
    • January 27, 2014
      ✓ 
      Patent use: TREATMENT OF ASTHMA
    • July 27, 2014
      ✓ 
      Pediatric exclusivity
  • Use of mometasone furoate for treating airway passage and lung diseases
    Patent 6,057,307
    Issued: May 2, 2000
    Inventor(s): Sequeira; Joel A. & Cuss; Francis M. & Nolop; Keith B. & Chaudry; Imtiaz A. & Nagabhushan; Nagamani & Patrick; James E. & Cayen; Mitchell
    Assignee(s): Schering Corporation
    The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.
    Patent expiration dates:
    • January 27, 2014
      ✓ 
      Patent use: TREATMENT OF ASTHMA
      ✓ 
      Drug product
    • July 27, 2014
      ✓ 
      Pediatric exclusivity
  • Chlorofluorocarbon-free mometasone furoate aerosol formulations
    Patent 6,068,832
    Issued: May 30, 2000
    Inventor(s): Berry; Julianne & Sequeira; Joel A. & Chaudry; Imtiaz A.
    Assignee(s): Schering Corporation
    The invention relates to suspension aerosol formulations which exhibit stable particle sizes, containing mometasone furoate, about 1 to about 10 weight percent ethanol and 1,1,1,2,3,3,3-Heptafluoropropane as the propellant. A surfactant, such as oleic acid, can also be included. These formulations are suitable for use in metered dose inhalers.
    Patent expiration dates:
    • August 27, 2017
      ✓ 
      Patent use: TREATMENT OF ASTHMA
      ✓ 
      Drug product
  • Use of mometasone furoate for treating airway passage and lung diseases
    Patent 6,677,323
    Issued: January 13, 2004
    Inventor(s): Joel A.; Sequeira & Francis M.; Cuss & Keith B.; Nolop & Imtiaz A.; Chaudry & Nagamani; Nagabhushan & James E.; Patrick & Mitchell; Cayen
    Assignee(s): Schering Corporation
    The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.
    Patent expiration dates:
    • January 27, 2014
      ✓ 
      Patent use: TREATMENT OF ASTHMA
  • Combinations of formoterol and mometasone furoate for asthma
    Patent 7,067,502
    Issued: June 27, 2006
    Inventor(s): Hassan; Ian Francis & Clarke; Jeremy Guy & Danahay; Henry Luke
    Assignee(s): Novartis AG
    A medicament containing, separately or together, (A) formoterol or a pharmaceutically acceptable salt thereof or a solvate of formoterol or a solvate of the salt and (B) mometasone furoate, for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease.
    Patent expiration dates:
    • May 21, 2020
      ✓ 
      Patent use: TREATMENT OF ASTHMA
      ✓ 
      Drug product
  • Combination of formoterol and mometasone furoate for asthma
    Patent 7,566,705
    Issued: July 28, 2009
    Inventor(s): Hassan; Ian F & Clarke; Jeremy G & Danahay; Henry L
    Assignee(s): Novartis AG
    A medicament containing, separately or together, (A) formoterol or a pharmaceutically acceptable salt thereof or a solvate of formoterol or a solvate of the salt and (B) mometasone furoate, for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease.
    Patent expiration dates:
    • May 21, 2020
      ✓ 
      Patent use: TREATMENT OF ASTHMA
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web1)